

Cognizin® Structure/Function claims

The following claims are provided for informational purposes and should be reviewed by your legal counsel prior to use in marketing materials, including product labels.

- 1. Cognizin® supports focus and attention*4,10,11,13 (≥250 mg)
- 2. Cognizin® assists your ability to stay focused*4,10,11,13 (≥250 mg)
- 3. Cognizin® supports focus to reduce errors while on task*11,13 (≥250 mg)
- 4. Cognizin® supports energy utilization in the brain*5,7,9,15 (≥500 mg)
- 5. Cognizin® is a brain health ingredient that provides nutritional support for attention, focus and brain energy* 9,11,13 (≥250 mg)
- 6. Cognizin® to support brain and cognitive health *9,10,11,12,13
- 7. Cognizin® supports phospholipid metabolism in the brain*1,3,5,7,9
- 8. Cognizin® supports acetylcholine production*1,4,7
- 9. Cognizin® supports brain DNA synthesis and repair*1,4,7
- 10. Cognizin® Supports brain cell signaling*4,5,7,14
- 11. Cognizin® supports dopamine and norepinephrine production*4,7,14,15
- 12. Cognizin® helps support memory*^{16,17,18} (≥500 mg)
- 13. Cognizin® for memory Support*16,17,18 (≥500 mg)

For more information about Cognizin contact:

KYOWA HAKKO USA. INC.

Customer Service: 800.596.9252 info@kyowa-usa.com

600 Third Ave. 19th Floor Tel: 212.319.5353 New York, NY 10016 Fax: 212.421.1283

www.kyowa-usa.com www.cognizin.com



*These statements have not been evaluated by the Food and Drug Administration. This products is not intended to diagnose, treat, cure or prevent any disease.

References

- 1. Wurtman RJ et al. Biochem Pharmacol. 2000; 60(7):989-92.
- 2. Rao AM et al. J Neurosci Res. 1999; 58(5):697-705.
- 3. Lopez-Coviella I et al. J Neurochem. 1995; 65(2):889-94.
- 4. Conant R, Schauss AG. Alt Med Rev. 2004; 9:1, 17-31.
- 5. Babb SM et al. Psychopharmacology (Berl). 2002; 161:248-54.
- 6. Fiorvanti M, Yanagi M. The Cochrane Library, Oxford, England. 2006: Issue 4.
- 7. Secades JJ, Lorenzo JL. Meth Find Exp Clin Pharmacol. 2006; 27 (Suppl B):1-56.
- 8. Watanabe S et al. Folia Psychiatr Neurol Jpn. 1975; 29(1):67-76.
- 9. Silveri MM et al. NMR Biomed. 2008; 21(10):1066-75.
- 10. Spiers PA et al. Arch Neurol. 1996; 53:441-48.
- 11. McGlade E. et al., Food and Nutrition Sciences. 2012; 3:769-773.
- 12. Cotroneo AM, et al., Clin Intery Aging. 2013; 8: 131-7
- 13. McGlade E, et al. J Atten Disord, 2015.
- 14. Secades JJ, et al., Meth find exp clin pharmacol. 1995; 17 (Suppl B):1-54.
- 15. Stork C, et al., Molecular Psychiatry. 2005; 10: 900-919.
- 16. Alvarez A . Meth Find Exp Clin Pharmacol. 1997;19(3):201-210.
- 17. Spiers PA et al. Arch Neurol. 1996;53:441-48.
- 18. In-house data (not yet published)

For more information about Cognizin contact:

KYOWA HAKKO USA, INC.

Customer Service: 800.596.9252 info@kyowa-usa.com

600 Third Ave. 19th Floor New York, NY 10016 Tel: 212.319.5353 Fax: 212.421.1283 www.kyowa-usa.com www.cognizin.com